The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986 · cited 1×
“[11, 12] and help maintain BMD in postmenopausal women [13].”
BackgroundPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674 · cited 1×
“Aromatase inhibitor treatment is an accepted standard of care for postmenopausal women with hormone-receptor-positive (HR) breast cancer [1, 2] and may be used upfront or as sequential treatment with tamoxifen [3–5].”
BackgroundSelf-citationEndocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Self-citationCoombes, R., Kilburn, L., Snowdon, C., Paridaens, R., Coleman, R., Jones, S., Jassem, J., Van de Velde, C., Delozier, T., Alvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 907
Self-citationDunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 796
Self-citationBreast-Cancer Adjuvant Therapy with Zoledronic Acid
Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., Gil, M., Houston, S. J., Grieve, R. J., Barrett-Lee, P. J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105195 · Cited by 424
Self-citationPreclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Breast-cancer Adjuvant Therapy With Zoledronic Acid
Coleman, R. E., Marshall, H. C., Cameron, D., et al. (2011) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 413
Self-citationEastell, R., Adams, J. E., Coleman, R. E., Howell, A., Hannon, R. A., Cuzick, J., Mackey, J. R., Beckmann, M. W., & Clack, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0726 · Cited by 407
Self-citationGnant, M., Mlineritsch, B., Luschin-Ebengreuth, G., Kainberger, F., Kässmann, H., Piswanger-Sölkner, J. C., Seifert, M., Ploner, F., Menzel, C., Dubsky, P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70204-3 · Cited by 396
Brufsky, A., Harker, W. G., Beck, J. T., Carroll, R., Tan-Chiu, E., Seidler, C., Hohneker, J., Lacerna, L., Petrone, S., & Perez, E. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3744 · Cited by 321
Eidtmann, H., de Boer, R., Bundred, N., Llombart-Cussac, A., Davidson, N., Neven, P., von Minckwitz, G., Miller, J., Schenk, N., & Coleman, R. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq217 · Cited by 281
Self-citationBundred, N. J., Campbell, I. D., Davidson, N., DeBoer, R. H., Eidtmann, H., Monnier, A., Neven, P., von Minckwitz, G., Miller, J. C., Schenk, N. L., et al. (2008) · Cancer · doi:10.1002/cncr.23259 · Cited by 218
Self-citationBrufsky, A. M., Harker, W. G., Beck, J. T., Bosserman, L., Vogel, C., Seidler, C., Jin, L., Warsi, G., Argonza‐Aviles, E., Hohneker, J., et al. (2012) · Cancer · doi:10.1002/cncr.26313 · Cited by 192
Goss, P. E., Ingle, J. N., Pater, J. L., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Shepherd, L. E., Pritchard, K. I., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6798 · Cited by 191
Self-citationNatural History of Bone Loss over 6 Years among Premenopausal and Early Postmenopausal Women
Bainbridge, K. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf049 · Cited by 109
Shapiro, C. L., Halabi, S., Hárs, V., Archer, L. E., Weckstein, D. J., Kirshner, J. J., Sikov, W. M., Winer, E. P., Burstein, H. J., Hudis, C. A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.024 · Cited by 102
Potential Anticancer Properties of Bisphosphonates
Neville-Webbe, H. L., Gnant, M., & Coleman, R. E. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.06.008 · Cited by 67
Self-citationColeman, R. E., Bundred, N. J., Boer, R. D., Llombarto, A., Campbell, I. D., Neven, P., Barrios, C. H., Dias, R., Miller, J. C., & Brufsky, A. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-4082 · Cited by 65
Self-citationThe backbone of progress – preclinical studies and innovations with zoledronic acid
Green, J. R., & Guenther, A. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(11)70003-8 · Cited by 38
Bone resorption versus estrogen loss following oophorectomy and menopause
Ohta, H., Makita, K., Komukai, S., & Nozawa, S. (2002) · Maturitas · doi:10.1016/s0378-5122(02)00180-9 · Cited by 29
Cited by
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Self-citationHarbeck, N., & Gnant, M. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,280
Bone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R., Body, J. J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 564
Self-citationLuminal breast cancer: from biology to treatment
Ignatiadis, M., & Sotiriou, C. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.124 · Cited by 469
Metadata
- Authors
- Coleman, R., de Boer, R., Eidtmann, H., Llombart, A., Davidson, N., Neven, P., von Minckwitz, G., Sleeboom, H. P., Forbes, J., Barrios, C., Frassoldati, A., Campbell, I., Paija, O., Martin, N., Modi, A., & Bundred, N.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 24
- Issue
- 2
- Pages
- 398-405
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2163949875
- Cited by
- 339
- References
- 23
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.